Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 4/20 | 0.33 |
| ▸ | RHEB | Q15382 | 2/20 | 0.33 |
| ▸ | F2 | P00734 | 2/20 | 0.32 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.30 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.30 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.30 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.30 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.30 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.30 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30217071 | 1.00 | TRPA1 (0.34) | TRPA1DRD1F10RHEBF2 | |
| SCHEMBL30967808 | 0.88 | TRPA1 (0.34) | TRPA1DRD1RHEBPRKAB2PRKAG1 | |
| SCHEMBL29237596 | 0.88 | TRPA1 (0.34) | TRPA1DRD1RHEBPRKAB2PRKAG1 | |
| SCHEMBL27382327 | 0.88 | TRPA1 (0.36) | TRPA1DRD1F10RHEBF2 | |
| SCHEMBL27265231 | 0.86 | TRPA1 (0.34) | TRPA1RHEBF2 | |
| SCHEMBL30217023 | 0.85 | TRPA1 (0.33) | TRPA1DRD1RHEB | |
| SCHEMBL29237313 | 0.85 | TRPA1 (0.33) | TRPA1DRD1RHEB | |
| SCHEMBL31108627 | 0.84 | TRPA1 (0.33) | TRPA1RHEB | |
| SCHEMBL30217304 | 0.84 | TRPA1 (0.33) | TRPA1RHEB | |
| SCHEMBL27265135 | 0.84 | TRPA1 (0.33) | TRPA1RHEB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239784-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION | 2024-07-18 | — | — | US | disclosed |
| US-20240239784-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION | 2024-07-18 | — | — | US | disclosed |
| CN-118201919-A | Indole compounds and methods of use | 健赞公司 | 2024-06-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239784-A1 | INDOLE COMPOUNDS AND METHODS OF USE | CFTR, INMT, IDO1 | TRPA1 66/4885DRD1 1043/4885F10 3750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.